Welcome to our dedicated page for Cidara Theraptcs SEC filings (Ticker: CDTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cidara Therapeutics, Inc. (CDTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a former Nasdaq-listed biotechnology issuer. These documents include current reports on Form 8-K, financing-related filings, and other materials that describe Cidara’s clinical development plans, capital structure changes, government agreements, and its acquisition by Merck.
For investors and researchers analyzing Cidara’s business, the company’s 8-K filings are especially important. They detail key events such as the Agreement and Plan of Merger with Merck Sharp & Dohme LLC and a Merck subsidiary, the terms of the cash tender offer for all outstanding shares of common and Series A preferred stock, and the planned merger that will make Cidara a wholly owned subsidiary of Merck. These filings also outline conditions to closing, tender offer mechanics, termination fees, and other transaction terms.
Other 8-K reports describe Cidara’s clinical and regulatory progress with CD388. For example, filings explain updates to the planned Phase 3 registrational trial following an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), including expansion of the ANCHOR study population and the intention to seek biologics license application (BLA) approval based on a single Phase 3 study. Additional filings summarize positive topline results from the Phase 2b NAVIGATE trial and provide context on safety and prevention efficacy data.
Cidara’s filings also cover its Award/Contract with the Biomedical Advanced Research and Development Authority (BARDA) to support expanded manufacturing and clinical development of CD388, including base-period funding for onshoring manufacturing to the United States and potential option funding for further studies. Capital markets transactions, such as underwritten public offerings of common stock and suspension of an at-the-market (ATM) prospectus, are documented in 8-Ks that describe underwriting agreements, share issuance, and related legal opinions.
On Stock Titan, these SEC filings are updated from EDGAR and can be paired with AI-powered summaries that highlight the main points of each document. Users can quickly see what each 8-K, registration-related filing, or other report means for Cidara’s clinical programs, financing, and merger process. While Cidara’s common stock is expected to cease trading on the Nasdaq Global Market following completion of its merger with Merck, its historical filings remain a key resource for understanding the evolution of CD388, the Cloudbreak platform, and the corporate steps leading to the acquisition.
Cidara Therapeutics director Carin Canale-Theakston reported the cash-out of stock options in connection with Cidara’s acquisition by Merck. On January 7, 2026, a Merck subsidiary completed a tender offer for all outstanding Cidara common and Series A preferred shares and then merged into Cidara, which became a wholly owned Merck subsidiary.
Immediately before the merger became effective, each of the director’s outstanding stock options became fully vested and exercisable, then was cancelled at the effective time and converted into the right to receive cash. The cash amount for each option equals the number of common shares subject to the option multiplied by the excess of $221.50 per share over the option’s exercise price. The reported option grants, which had exercise prices ranging from $10.6 to $50.2 and various expiration dates from 2031 to 2035, now show 0 derivative securities owned following these transactions. All exercise prices and share amounts were adjusted for Cidara’s 1-for-20 reverse stock split on April 24, 2024.
Cidara Therapeutics director Bonnie L. Bassler reported the cash-out of her remaining equity as Cidara was acquired by Merck. On January 7, 2026, a Merck subsidiary completed a tender offer and merger in which each Cidara common share was converted into the right to receive $221.50 in cash and each Series A preferred share into $15,505.00 in cash, both without interest and subject to withholding taxes. Bassler disposed of 15 common shares at $221.50 per share and all reported stock options were canceled at the merger’s effective time in exchange for cash based on the spread between $221.50 and each option’s exercise price. All amounts reflect a 1-for-20 reverse stock split completed on April 24, 2024.
Cidara Therapeutics director Chrysa Mineo reported the cash-out of her equity in connection with Merck’s acquisition of the company. On January 7, 2026, a Merck subsidiary completed a tender offer and merger that turned Cidara into a wholly owned Merck subsidiary. Each common share and Series A preferred share was converted into the right to receive cash.
Mineo disposed of 3,320 common shares at $221.50 per share, leaving her with no directly held common stock. Multiple stock options to buy Cidara common shares, with exercise prices adjusted for a prior 1‑for‑20 reverse split, were also fully vested and then canceled at the merger’s effective time. Each option was converted into a cash right equal to the number of shares underlying the option multiplied by the excess of $221.50 over the option’s exercise price.
Cidara Therapeutics director reports option cancellation in Merck buyout
Director Theodore R. Schroeder reported the disposition of multiple stock options for Cidara Therapeutics, Inc. on January 7, 2026. According to the disclosed merger agreement, Merck Sharp & Dohme LLC, through a subsidiary, completed a tender offer for all outstanding common and Series A preferred shares of Cidara and then merged the subsidiary into Cidara, which continues as a wholly owned subsidiary of Merck.
Immediately prior to and contingent upon the effective time of the merger, each outstanding option became fully vested and exercisable and, to the extent it remained unexercised, was cancelled and converted into a right to receive cash. The cash amount for each option equals the number of common shares subject to the option multiplied by the excess of $221.50 per share over the option’s exercise price, with all derivative positions reported in this filing reduced to zero after the transactions.
Cidara Therapeutics director Daniel D. Burgess reported the disposition of his remaining equity in the company on January 7, 2026, in connection with the completion of Merck’s acquisition of Cidara. A total of 150 shares of common stock, held indirectly through his spouse, were disposed of at $221.50 per share, leaving no common shares reported as beneficially owned.
The filing also shows that multiple stock options covering various amounts of Cidara common shares were fully vested and then canceled at the merger effective time, with each option converted into a cash payment equal to its intrinsic value based on the $221.50 per share merger consideration. All option positions are reported at 0 following these transactions. The share and option figures reflect a 1‑for‑20 reverse stock split effected on April 24, 2024.
Cidara Therapeutics President & CEO Jeffrey Stein reported the disposition of all his Cidara securities in connection with Merck’s acquisition of the company. On January 7, 2026, common shares held directly, and indirectly through his son and a trust, were tendered and converted into the right to receive $221.50 per common share in cash under the merger terms.
The filing also shows that all of Stein’s employee stock options, covering various numbers of common shares at different exercise prices, were cancelled at the effective time of the merger and converted into cash based on the excess of $221.50 per share over each option’s exercise price. All reported positions show 0 shares or options remaining, reflecting Cidara’s completion of the merger as a wholly owned subsidiary of Merck.
Cidara Therapeutics Chief Financial Officer Frank Karbe reported the cash-out of his equity holdings in connection with Merck’s acquisition of the company. On January 7, 2026, he disposed of 7,526 shares of Cidara common stock at $221.50 per share in the tender offer and merger, and a further 43,125 shares were reduced to zero balance as they were converted into the right to receive cash.
The filing also shows 115,000 employee stock options were cancelled on January 7, 2026 and converted into cash based on the spread between the $221.50 merger price and their exercise price. Under the Merger Agreement, all outstanding common shares were exchanged for $221.50 per share and all Series A preferred shares for $15,505.00 per share in cash, and Cidara became a wholly owned subsidiary of Merck.
Cidara Therapeutics, Inc. completed its sale to Merck, with all outstanding common and Series A preferred shares acquired under a merger agreement dated November 13, 2025. On January 7, 2026, each common share was exchanged for $221.50 in cash and each Series A preferred share for $15,505.00 in cash, both without interest and subject to withholding taxes.
COO & CLO Shane Ward reported the disposition of 25,083 common shares at $221.50 per share, leaving no directly held common stock. Multiple employee stock options covering various numbers of common shares and exercise prices were also fully vested and then cancelled at the merger’s effective time, with each option converted into a cash right equal to the number of underlying shares multiplied by the excess of $221.50 over the option exercise price.
Cidara Therapeutics, Inc. Chief Medical Officer Nicole Negar Davarpanah reported the cash-out of her equity holdings in connection with the company’s merger with Merck Sharp & Dohme LLC. On January 7, 2026, a Merck subsidiary completed a tender offer and subsequent merger, making Cidara a wholly owned Merck subsidiary.
Under the Merger Agreement, each Cidara common share was exchanged for $221.50 per share in cash, and each Series A preferred share for $15,505.00 per share in cash, both without interest and subject to tax withholding. The filing shows dispositions of common stock at $221.50 per share, and the cancellation of restricted stock units and employee stock options in exchange for cash based on the $221.50 common share value, less any applicable option exercise prices. Following these transactions, the reporting person no longer holds Cidara common stock or options.
Cidara Therapeutics’ President & CEO Jeffrey Stein, a director of the company, filed an updated Form 4 covering historical transactions in Cidara common stock. The filing restates prior reports from 2016, 2017, 2020 and 2021 to correct how many shares were shown as beneficially owned by him and to reclassify certain purchases as made by a trust rather than directly by him. All share and price figures in the table have been adjusted for the company’s 1‑for‑20 reverse stock split effected on April 24, 2024.
The filing also reports a gift of common stock on December 31, 2021 from Stein to his sons, with shares held both by a trust and by a son. The disclosure notes that he disclaims beneficial ownership of the shares held by his independent son, and states that the report should not be taken as an admission that he is the beneficial owner of those shares for Section 16 or any other purpose.